SLC2A1 and hyperinsulinemic hypoglycemia, familial, 4: The main indication of KD in children is the treatment of refractory epilepsy, but it is also the causal therapy of GLUT1 deficiency, a metabolic disorder characterized by epilepsy, developmental delay and movement disorders [14, 15].